Incretin agonists are being developed as treatment for various metabolic disorders targeting glucagon, glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors or their combination as either bi- or tri-modal incretin agonists. The development of these multimodal drugs is dependent on the understanding of the overlapping pharmacology of activating different incretin receptors.
Antaros Medical has a powerful tool set for tailoring solutions to measure receptor occupancy of both bi- and trimodal incretin agonists. Our proprietary PET tracers, [68Ga]-Tuna-2 targeting the glucagon receptor and [68Ga]S02-GIP-T4 targeting the GIP receptor, together with an additional PET-tracer for the GLP-1 receptor, can provide insights to help set dosing and generate evidence on target engagement.
Our proprietary glucagon PET-tracer has now been granted patent also in Japan, further strengthening our platform to move new metabolic treatments forward.
Read more about our incretin tracers in previous news posts:
- PET imaging of the glucagon like peptide-1 receptor
- Unique data on Antaros Medical’s proprietary GIP-receptor PET ligand published in Diabetes
- First clinical PET study measuring the receptor occupancy of a dual GLP1/glucagon receptor agonist is now published
- The GIP-receptor PET ligand collaboration between Antaros Medical and Sanofi generated a lot of interest at EASD 2020